|
 Chromatic response and evolving Au nanoparticle dimensionality in lysozyme and anti-lysozyme system. Image courtesy of Prof David Mainwaring, RMIT University.
This technology aims to produce a fast, more cost-effective detection method for meningococcal disease by applying nanoparticle technology to provide a rapid readout.
The technology exploits the effects of either metallic or magnetic nanoparticulate surfaces, providing a diagnostic platform which avoids lengthy bacterial culturing and sample preparation currently required.
The market for rapid, specific and deployable diagnostics is rapidly expanding as community demands for health care grow and pressures on the health care budget increase. Selective detection on either nanoparticle or planar platforms offers a significant cost effective opportunity to develop products for the diagnosis of both pathogenic and genetic diseases.
Prototype Device Development
 Quintain is also working with Melbourne-based company Charlwood Design, to develop a prototype clinical device for meningococcal disease. Two concepts are under development; the first is a qualitative point-of-care or bedside test which will incorporate a mechanism for safe, simple sample delivery to the test. The second format is a laboratory-based test which will offer the advantages of the point-of-care test, in addition to multiplexing and quantitation. Both formats will be easily adaptable for the detection of disease states such as infectious diseases, cardiovascular disease and cancer.
More information at NanoVic.
|
